13G Filing: Highbridge Capital Management and Adverum Biotechnologies Inc. (ADVM)

Page 1 of 8

Adverum Biotechnologies Inc. (NASDAQ:ADVM): Glenn Russell’s Highbridge Capital Management filed an amended 13D.

You can check out Highbridge Capital Management’s latest holdings and filings here.

Please follow Highbridge Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Highbridge Capital Management or update its stock holdings.

Glenn Russell Dubin
Glenn Russell Dubin
Highbridge Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Highbridge Capital Management 0 2,500,000 0 2,500,000 2,500,000 5.55%
199 0 2,500,000 0 2,500,000 2,500,000 5.55%
Glenn Russell Dubin
Glenn Russell Dubin
Highbridge Capital Management

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No.  )*

Adverum Biotechnologies,
Inc.

(Name of Issuer)

Common Stock,
par value $0.0001 per share

(Title of Class of Securities)

00773U108

(CUSIP Number)

December
5, 2017

(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 8 Pages)

______________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Adverum Biotechnologies Inc. (NASDAQ:ADVM)

Page 1 of 8